OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across th ...

Core Insights - Daxor Corporation's BVA technology significantly reduces hospital readmissions and improves survival rates in high-cost heart failure segments, validated by new clinical data presented at the HFSA Annual Scientific Meeting [1][3] - The newly FDA-cleared BVA analyzer is expected to capture a substantial share of the multi-billion-dollar market due to its enhanced ease of use, speed, and over 95% accuracy [2][3] Clinical Validation - Clinical findings indicate that patients optimally managed with BVA technology experienced zero unplanned readmissions, contrasting sharply with 57-77% for those with imbalances in blood volume [7] - The use of BVA-guided care in LVAD implantation resulted in improved outcomes, increasing 30-day survival from 90.3% to 93.6% and 1-year survival from 79.6% to 87.8%, while reducing 30-day readmissions from 28.6% to 18.5% [7] - Patients with Cardiac Amyloidosis showed significantly higher total blood and plasma volumes, indicating the diagnostic potential of BVA for accurate treatment [7] Company Overview - Daxor Corporation addresses the critical issue of accurately measuring blood volume, which is essential for optimal care in high-cost medical conditions like heart failure [4] - The company has 50 years of experience and operates a state-of-the-art manufacturing facility, positioning it for accelerated market expansion [4]

Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer (BVA), signaling a new era of da ...

Core Insights - The study published in the Journal of Critical Care reveals frequent inaccuracies in clinical assessments of fluid status in critically ill patients, particularly those with sepsis and COVID-19 [1][2] - Daxor Corporation's BVA technology is highlighted as a solution to improve fluid management in critical care settings, emphasizing the need for accurate blood volume measurement [4][5] Study Findings - A significant percentage of patients were misclassified during clinical assessments, with 48% of COVID-19 patients incorrectly deemed hypervolemic when they were actually hypovolemic [8] - The study indicates that the albumin transudation rate (ATR) was persistently elevated in both sepsis and COVID-19 patients, suggesting ongoing capillary leakage [8] - Sepsis patients exhibited a higher ATR compared to COVID-19 patients, indicating more severe endothelial dysfunction despite lower admission severity scores [8] Company Positioning - Daxor's FDA-approved BVA-100™ Analyzer was utilized in the study, showcasing its capability to provide objective measurements of total blood volume and ATR [4] - The company has received FDA clearance for a new rapid BVA system, which is three times faster than the BVA-100™ and maintains over 95% accuracy, addressing urgent diagnostic needs in critical care [5][6] - Daxor is positioned for revenue expansion in critical care medicine, supported by new data, funding opportunities, and advancements in its technology [6][9]

Core Insights - Daxor Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1] - The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET [1] Company Overview - Daxor Corporation is addressing a significant issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays [3] - The company has developed a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic system that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor has 50 years of experience in the field and operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S., positioning it for market expansion [3] Investor Engagement - Investors interested in the presentation can register for the conference through a provided link [2] - CEO Michael Feldschuh will be available for one-on-one meetings with registered investors at the conference [2] - For further inquiries, investors can contact Bret Shapiro at CORE IR via phone or email [2][6]

Core Insights - Daxor Corporation has achieved significant milestones in 2025, including FDA clearance for a new rapid Blood Volume Analysis (BVA) system, marking a transformative moment for the company [4][8] - The company reported a 73% increase in unaudited revenues for the first half of 2025 compared to the same period in 2024, driven by sales of diagnostic kits and military contracts [6][8] - Daxor's net asset value increased to $36.6 million as of June 30, 2025, reflecting a $3.97 million increase from the previous year [6][8] Product Innovation - The new BVA system is three times faster, portable, and smaller than the existing BVA-100, while maintaining the ability to measure total blood volume, red blood cell volume, plasma volume, and albumin transudation rate [4][8] - The company is committed to rolling out the new BVA system and accelerating commercial operations alongside ongoing research and development for additional products [8] Financial Performance - Daxor's operating division reported a significant revenue increase, with net asset value per share rising to $7.15, up $0.40 from the previous year [6][8] - The company experienced a net decrease in unrealized appreciation on investments but reported net realized gains of $468,212 for the first half of 2025 [6] Market Adoption and Clinical Validation - The adoption of Daxor's BVA technology has accelerated, with new accounts contributing to revenue growth and clinical acceptance [6][8] - A significant study published in the American Heart Journal highlighted the utility of BVA technology in managing heart failure, showing that patients identified as euvolemic had 2.61 times better survival rates [9] Industry Engagement - Daxor actively engaged with the medical community through industry events to showcase its technology and foster awareness among cardiovascular professionals [7][9] - The company exhibited at major conferences, further solidifying its presence in the healthcare sector [9]

Core Insights - Daxor Corporation has achieved FDA 510(k) clearance for its next-generation, rapid, compact, hand-held Blood Volume Analyzer (BVA), marking a significant milestone for the company [1] - The Nasdaq Closing Bell Ceremony held on August 8, 2025, celebrated this achievement and is now available for replay [2] Company Overview - Daxor Corporation is addressing a critical issue in healthcare, specifically the inability to accurately measure blood volume, which can lead to suboptimal patient care and increased hospital stays for conditions like heart failure [3] - The company has over 50 years of experience in innovation and offers a patented, FDA-cleared Blood Volume Analysis diagnostic that provides real-time, precise data, enabling clinicians to make better treatment decisions [3] - Daxor operates a state-of-the-art 20,000-square-foot manufacturing facility in the U.S. and is ISO certified, positioning itself for market expansion [3]

Core Insights - Daxor Corporation has received FDA 510(k) clearance for its next-generation Blood Volume Analyzer (BVA), which is expected to meet high demand due to its speed, simplicity, and clinical precision [1][2] - The new BVA device allows for precise fluid management in various clinical conditions, addressing a significant healthcare burden associated with volume derangement [2][4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, focusing on addressing the inability to accurately measure blood volume, which leads to suboptimal care and increased healthcare costs [6][8] - The company has over 50 years of experience and has shipped more than 75,000 tests, collaborating with leading medical institutions to validate the effectiveness of BVA-guided care [5][6] Product Features - The new BVA device is rapid, hand-held, and modular, enabling its use in various clinical settings, including cardiology, nephrology, and emergency medicine [4][7] - It provides critical results three times faster than traditional methods, weighs only 7 lbs, and delivers laboratory-grade diagnostic precision [7] Clinical Impact - Studies indicate that BVA-guided care can significantly reduce one-year mortality in heart failure patients by 86%, decrease hospital stays, and lower readmission rates by 56% [3][5] - The device is particularly beneficial for managing conditions like heart failure, critical care, and sepsis, which collectively affect millions of patients annually [2][3]

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) technology into three new hospitals, highlighting the increasing recognition of BVA's role in improving patient outcomes and reducing healthcare costs [1][2] - The growth is attributed to the integration of Daxor's CLIA-certified ezBVA Lab service and on-site blood volume analyzers, which are expected to drive accelerated sales growth throughout 2025 as clinicians adopt BVA for fluid management [1][2] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at major hospital centers in the U.S., significantly impacting surgical and medical conditions, particularly in reducing mortality and readmissions in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Recent Developments - Recent sales wins include the adoption of ezBVA Lab services in a Tennessee medical center for cardiology applications, integration of BVA with an on-site analyzer in an Arkansas hospital for advanced heart care, and utilization of ezBVA Lab service in a leading referral hospital serving Arizona, Nevada, and Utah for advanced heart failure patients [5]

Core Insights - Daxor Corporation has announced significant findings from Duke University Medical Center regarding the effectiveness of Blood Volume Analysis (BVA) in identifying anemia types in heart failure patients [1][3] - The study emphasizes that standard blood tests are insufficient for accurately diagnosing anemia, highlighting the need for BVA in clinical practice [2][3] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic test for quantifying blood volume status [4] - The company has conducted over 70,000 tests across leading hospitals in the U.S., contributing to improved patient outcomes in heart failure and critical care [4] Research Findings - The study revealed that among heart failure patients diagnosed with anemia, 60% had true anemia while 40% had dilutional pseudo-anemia, indicating a critical distinction in treatment needs [6] - Patients with dilutional pseudo-anemia experienced higher hospitalization rates compared to those with no anemia or true anemia, underscoring the importance of accurate anemia classification [6] - Heart failure patients with true anemia or RBCM deficit showed poorer exercise capacity, linking anemia type to patient outcomes [6]